Clinical Trial Update: Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bi-weekly gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Carcinoma Non-resectable

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Western Regional Medical Center | Conditions: Pancreatic Carcinoma Non-resectable, Stage IV Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-12-04